The use of hypofractionated schedules in proton therapy is rapidly increasing. Their application has several advantages, including the reduction of overall treatment time and direct and indirect costs, the improvement of the patients’ quality of life, and the increase of the overall system capacity. In the era of “green treatments” and a still limited number of Proton Therapy facilities worldwide, these benefits could translate into more sustainable and fair management of the available resources.

In this webinar, Prof. Roberto Orecchia, Prof. Barbara Jereczek and distinguished invited speakers highlight the radiobiological bases and clinical applications of hypofractionated proton therapy in daily clinical practice, offering an updated review of the literature as well as results of their clinical experiences. Watch the webinar recording now and discover: 

• (2:00) Prof. Barbara Jereczek’s introduction and overview of the hypofractionated radiotherapy clinical applications;
• (06:45) Prof. Marco Durante’s presentation of the radiobiological basis of hypofractionation in proton therapy;
• (27:00) Dr. Maciej Pelak’s experience of normo- vs. hypofractionation at the MedAustron Ion Therapy Center;
• (42:50) Dr. Dante Amelio’s experience with hypofractionation in tumors of the central nervous system;
• (58:50) Dr. Jiri Kubes’s experience with hypofractionation in prostate cancer;
• (1:12:15) Dr. Daniela Alterio’s review of the literature on hypofractionated re-irradiation.

Organizational Support: Campus@iba-group.com